Research ExplorerPublicationsNeue Substanzen in der Therapie der Angina pectoris

Neue Substanzen in der Therapie der Angina pectoris

Standard

Neue Substanzen in der Therapie der Angina pectoris. / Meinertz, T; Köster, R.

In: INTERNIST, Vol. 52, No. 7, 07.2011, p. 894-896.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Meinertz, T & Köster, R 2011, 'Neue Substanzen in der Therapie der Angina pectoris', INTERNIST, vol. 52, no. 7, pp. 894-896. https://doi.org/10.1007/s00108-011-2854-z

APA

Meinertz, T., & Köster, R. (2011). Neue Substanzen in der Therapie der Angina pectoris. INTERNIST, 52(7), 894-896. https://doi.org/10.1007/s00108-011-2854-z

Vancouver

Meinertz T, Köster R. Neue Substanzen in der Therapie der Angina pectoris. INTERNIST. 2011 Jul;52(7):894-896. https://doi.org/10.1007/s00108-011-2854-z

Bibtex

@article{6b7b924d20de490a96e0198ed5e89415,
title = "Neue Substanzen in der Therapie der Angina pectoris",
abstract = "There is a renaissance of medical treatment of chronic angina pectoris despite of advances in interventional therapy. New drugs include nicorandil, ivabradine and ranolazine. Nicorandil dilates venous and arterial vessels via relaxation of smooth muscle cells. Since the drug has only recently been approved, the German experience is limited. Ivabradine exerts an anti-anginous effect by selective action on the sinus node with reduction of heart rate. Multiple studies have demonstrated its anti-anginal efficacy, which has also been shown if it was used as an additional therapy to classic anti-anginal treatment. Its use is reasonable as a substitute for beta-blockers or as an {"}add-on therapy{"} combined with beta-blockers, if the target heart rate for treatment of angina pectoris has not been reached. Ranolazine delays the late sodium current into the myocytes. Thereby, it improves the diastolic ventricular function and the microcirculation of the myocardium. Several large studies confirmed the anti-anginal efficacy of the drug. Currently it is used if angina pectoris still occurs under a combined treatment with different classic anti-anginal drugs.",
keywords = "Acetanilides/adverse effects, Angina Pectoris/drug therapy, Benzazepines/adverse effects, Coronary Artery Disease/drug therapy, Cyclic Nucleotide-Gated Cation Channels/drug effects, Double-Blind Method, Drug Approval, Enzyme Inhibitors/adverse effects, Humans, Ivabradine, Nicorandil/adverse effects, Piperazines/adverse effects, Randomized Controlled Trials as Topic, Ranolazine, Vasodilator Agents/adverse effects",
author = "T Meinertz and R K{\"o}ster",
year = "2011",
month = jul,
doi = "10.1007/s00108-011-2854-z",
language = "Deutsch",
volume = "52",
pages = "894--896",
journal = "INTERNIST",
issn = "0020-9554",
publisher = "Springer",
number = "7",

}

RIS

TY - JOUR

T1 - Neue Substanzen in der Therapie der Angina pectoris

AU - Meinertz, T

AU - Köster, R

PY - 2011/7

Y1 - 2011/7

N2 - There is a renaissance of medical treatment of chronic angina pectoris despite of advances in interventional therapy. New drugs include nicorandil, ivabradine and ranolazine. Nicorandil dilates venous and arterial vessels via relaxation of smooth muscle cells. Since the drug has only recently been approved, the German experience is limited. Ivabradine exerts an anti-anginous effect by selective action on the sinus node with reduction of heart rate. Multiple studies have demonstrated its anti-anginal efficacy, which has also been shown if it was used as an additional therapy to classic anti-anginal treatment. Its use is reasonable as a substitute for beta-blockers or as an "add-on therapy" combined with beta-blockers, if the target heart rate for treatment of angina pectoris has not been reached. Ranolazine delays the late sodium current into the myocytes. Thereby, it improves the diastolic ventricular function and the microcirculation of the myocardium. Several large studies confirmed the anti-anginal efficacy of the drug. Currently it is used if angina pectoris still occurs under a combined treatment with different classic anti-anginal drugs.

AB - There is a renaissance of medical treatment of chronic angina pectoris despite of advances in interventional therapy. New drugs include nicorandil, ivabradine and ranolazine. Nicorandil dilates venous and arterial vessels via relaxation of smooth muscle cells. Since the drug has only recently been approved, the German experience is limited. Ivabradine exerts an anti-anginous effect by selective action on the sinus node with reduction of heart rate. Multiple studies have demonstrated its anti-anginal efficacy, which has also been shown if it was used as an additional therapy to classic anti-anginal treatment. Its use is reasonable as a substitute for beta-blockers or as an "add-on therapy" combined with beta-blockers, if the target heart rate for treatment of angina pectoris has not been reached. Ranolazine delays the late sodium current into the myocytes. Thereby, it improves the diastolic ventricular function and the microcirculation of the myocardium. Several large studies confirmed the anti-anginal efficacy of the drug. Currently it is used if angina pectoris still occurs under a combined treatment with different classic anti-anginal drugs.

KW - Acetanilides/adverse effects

KW - Angina Pectoris/drug therapy

KW - Benzazepines/adverse effects

KW - Coronary Artery Disease/drug therapy

KW - Cyclic Nucleotide-Gated Cation Channels/drug effects

KW - Double-Blind Method

KW - Drug Approval

KW - Enzyme Inhibitors/adverse effects

KW - Humans

KW - Ivabradine

KW - Nicorandil/adverse effects

KW - Piperazines/adverse effects

KW - Randomized Controlled Trials as Topic

KW - Ranolazine

KW - Vasodilator Agents/adverse effects

U2 - 10.1007/s00108-011-2854-z

DO - 10.1007/s00108-011-2854-z

M3 - SCORING: Review

C2 - 21713611

VL - 52

SP - 894

EP - 896

JO - INTERNIST

JF - INTERNIST

SN - 0020-9554

IS - 7

ER -